statements

ANG Lifesciences India Ltd.

BSE: 540694

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

26.82+1.3 (+4.97%)

25 Aug, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

ANG Lifesciences India Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	16.25	34.50	36.84	54.92	67.67	76.04	121.70	126.83	154.38	354.30	219.89	146.11	92.85	92.89	83.59
Cost of Operating Revenue	11.99	28.56	27.76	41.92	48.94	54.09	88.96	90.20	105.28	233.86	167.19	103.48	66.38	66.87	61.04
Gross Profit	4.26	5.94	9.08	13.00	18.73	21.96	32.74	36.63	49.10	120.44	52.70	42.63	26.46	26.02	22.55
Gross Margin	26.2	17.2	24.7	23.7	27.7	28.9	26.9	28.9	31.8	34.0	24.0	29.2	28.5	28.0	27.0
Total Operating Expenses	14.30	32.66	34.68	51.25	62.58	70.20	111.41	115.98	141.83	292.69	214.66	144.83	101.87	98.51	91.78
Operating Profit	1.95	1.84	2.17	3.67	5.09	5.85	10.29	10.85	12.55	61.61	5.23	1.28	-9.03	-5.62	-8.19
Operating Margin	12.0	5.3	5.9	6.7	7.5	7.7	8.5	8.6	8.1	17.4	2.4	0.9	-9.7	-6.1	-9.8
Financing Income/(Expense) - Net	-1.81	-1.46	-1.61	-1.61	-1.53	-1.58	-2.34	-2.87	-2.97	-8.91	-11.66	-10.43	-8.70	-7.93	-8.23
Profit before Taxes	0.15	0.45	0.60	2.22	3.81	4.95	8.11	8.41	10.14	53.50	2.63	-10.71	-15.70	-13.01	-15.86
Income Taxes	0.21	0.25	0.20	0.57	0.99	1.23	2.46	2.31	3.11	13.18	2.89	-0.57	-3.29	-1.93	-2.54
Profit after Tax	-0.06	0.19	0.40	1.65	2.82	3.72	5.65	6.10	7.03	40.32	-0.26	-10.14	-12.41	-11.08	-13.32
PAT Margin	-0.4	0.6	1.1	3.0	4.2	4.9	4.6	4.8	4.6	11.4	-0.1	-6.9	-13.4	-11.9	-15.9
EPS - Basic - ex Extraordinary Items	-0.05	0.15	0.31	1.28	2.18	2.87	4.36	4.70	5.42	31.11	-0.20	-7.77	-9.51	-8.43	-10.15
EPS - Diluted - ex Extraordinary Items	-0.05	0.15	0.31	1.28	2.18	2.87	4.36	4.70	5.42	31.11	-0.20	-7.77	-9.51	-8.43	-10.15
EBIT	1.95	1.84	2.17	3.67	5.09	5.85	10.29	10.85	12.55	61.61	5.23	1.28	-9.03	-5.62	-8.19
EBITDA	2.62	4.89	3.11	4.73	6.26	7.04	11.41	12.08	13.87	67.49	14.58	9.65	-2.27	0.71	-1.89
EBITDA Margin	16.1	14.2	8.4	8.6	9.3	9.3	9.4	9.5	9.0	19.0	6.6	6.6	-2.4	0.8	-2.3

Balance Sheet

Abridged

Understanding Balance Sheet

ANG Lifesciences India Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	PR	PR	PR	PR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	9.56	15.91	16.95	26.40	37.76	46.87	59.96	72.71	115.87	192.81	186.89	178.94	165.34	149.35
Long-Term Investments	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	3.52	1.03	0.15	0.24	0.24	0.24
Property Plant & Equipment - Net	11.42	9.04	8.78	9.02	8.97	21.04	20.76	20.94	23.86	92.61	88.15	58.40	57.19	50.61
Total Non-Current Assets	11.81	9.27	8.89	9.10	9.08	21.29	20.94	21.36	27.78	98.22	92.81	63.50	64.25	59.59
Total Assets	21.38	25.18	25.84	35.49	46.84	68.17	80.90	94.08	143.65	291.03	279.70	242.44	229.59	208.95
Total Current Liabilities	8.11	12.70	14.62	23.81	34.21	35.45	42.40	50.90	91.56	166.29	162.28	144.57	143.44	149.04
Long Term Debt	10.99	9.77	8.11	6.81	4.96	7.68	6.28	5.25	7.03	21.64	22.84	16.72	20.73	5.61
Total Non-Current Liabilities	10.99	9.77	8.11	6.91	5.14	9.55	9.73	8.62	10.51	40.97	31.20	21.59	22.18	7.02
Total Liabilities	19.11	22.47	22.73	30.72	39.35	45.00	52.13	59.52	102.07	207.26	193.49	166.16	165.62	156.06
Total Shareholders' Equity	2.27	2.71	3.12	4.77	7.49	23.17	28.77	34.56	41.58	83.77	86.22	76.28	63.98	52.89
Total Equity	2.27	2.71	3.12	4.77	7.49	23.17	28.77	34.56	41.58	83.77	86.22	76.28	63.98	52.89
Total Liabilities & Equity	21.38	25.18	25.84	35.49	46.84	68.17	80.90	94.08	143.65	291.03	279.70	242.44	229.59	208.95

Cash Flow

Abridged

Understanding Cash Flow Statement

ANG Lifesciences India Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	0.82	3.41	1.48	2.86	4.11	5.11	6.80	6.98	8.28	62.10	8.76	-14.34	-14.63	-4.71
Working Capital - Increase/(Decrease)	-10.23	-1.29	0.03	-2.61	-1.13	-5.81	-1.68	-5.02	-2.10	-45.05	6.51	-5.27	6.22	8.54
Net CF from Operating Activities	-9.40	2.11	1.51	0.25	2.98	-0.70	5.12	1.96	6.18	17.05	15.27	-19.61	-8.40	3.83
Capital Expenditures - Net	0.35	0.67	0.70	1.31	1.12	13.26	0.84	1.64	4.24	41.34	10.44	-18.93	3.75	-0.36
Net CF from Investing Activities	-0.35	-0.67	-0.70	-1.31	-1.15	-13.40	-0.77	-1.66	-7.70	-44.70	-9.97	19.36	-1.81	0.54
Dividends Paid - Cash - Total	-	-	-	-	-	-	-	-	-	1.04	-	-	-	-
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	12.01	-	-	-	-	2.00	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	9.93	-1.68	-0.89	1.63	-1.85	2.72	-1.41	-1.03	1.78	28.92	-7.32	0.24	10.06	-4.03
Net Cash Flow from Financing Activities	9.93	-1.43	-0.89	1.63	-1.95	14.68	-1.46	-1.08	1.78	27.89	-5.32	0.24	10.06	-4.03
Free Cash Flow to Equity	0.17	-0.23	-0.08	0.56	0.01	-11.25	2.87	-0.71	3.71	4.63	-2.50	-0.44	-2.10	0.15
Free Operating CF net dividend	-9.76	1.44	0.81	-1.06	1.86	-13.97	4.28	0.32	1.93	-25.33	4.83	-25.18	-12.16	3.39
Free Operating CF	-9.76	1.44	0.81	-1.06	1.86	-13.97	4.28	0.32	1.93	-24.30	4.83	-25.18	-12.16	3.39

Business Segment Analysis

FY End:

Mar 23

ANG Lifesciences India Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

Pharmaceutical (89.5%)₹ 207.01 CrPrinting and Packagings (10.5%)₹ 24.21 Cr

Assets

Pharmaceutical (87.4%)₹ 244.48 CrPrinting and Packagings (12.6%)₹ 35.22 Cr

Regional Segment Analysis

ANG Lifesciences India Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for ANG Lifesciences India Ltd.

Historical Segment Analysis

Track how ANG Lifesciences India Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Sales

Assets

Business

Regional

Business

We don't have enough data to show the Capex for ANG Lifesciences India Ltd..

Frequently Asked Questions

What is the revenue of ANG Lifesciences India Ltd.?

The latest trailing twelve month revenue of ANG Lifesciences India Ltd. is ₹ 83.59 Cr, reflecting a 1-year growth of -15.60% and a 3-year CAGR of -25.56%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of ANG Lifesciences India Ltd.?

The latest trailing twelve month net profit (PAT) of ANG Lifesciences India Ltd. is ₹ -13.32 Cr, with a 3-year earnings CAGR of -98.51%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of ANG Lifesciences India Ltd.?

The trailing twelve month EBITDA of ANG Lifesciences India Ltd. is approximately ₹ -8.19 Cr (based on an operating margin of -9.80%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of ANG Lifesciences India Ltd.?

The trailing twelve month Earnings Per Share (EPS) of ANG Lifesciences India Ltd. is -10.15. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of ANG Lifesciences India Ltd.?

The debt-to-equity ratio of ANG Lifesciences India Ltd. stands at 1.50. The interest coverage ratio is -0.99x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of ANG Lifesciences India Ltd.?

The estimated book value per share of ANG Lifesciences India Ltd. is 40.50 (derived from a P/B ratio of 0.66 and market price of ₹ 26.82), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of ANG Lifesciences India Ltd.?

The trailing twelve month operating cash flow of ANG Lifesciences India Ltd. is ₹ 3.83 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does ANG Lifesciences India Ltd. report consolidated or standalone financials?

ANG Lifesciences India Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.